Bios Partners

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies to protect and improve vision in patients with retinal diseases. Established in 2006, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway, offering potential protection for photoreceptors. Its drug programs are designed to address serious, vision-threatening conditions, including retinal detachment, ultimately aiming to enhance surgical outcomes and patient quality of life through the use of small-molecule peptides.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies to protect and improve vision in patients with retinal diseases. Established in 2006, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway, offering potential protection for photoreceptors. Its drug programs are designed to address serious, vision-threatening conditions, including retinal detachment, ultimately aiming to enhance surgical outcomes and patient quality of life through the use of small-molecule peptides.

Opus Genetics is a biotechnology company focused on developing gene therapies for ultra-rare blinding conditions. The company specializes in creating adeno-associated virus-based gene therapies aimed at treating rare retinal degenerative diseases. Opus Genetics addresses manufacturing challenges that hinder the delivery of these life-changing treatments, ensuring efficient access to therapies for patients with severe visual impairments.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies to protect and improve vision in patients with retinal diseases. Established in 2006, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway, offering potential protection for photoreceptors. Its drug programs are designed to address serious, vision-threatening conditions, including retinal detachment, ultimately aiming to enhance surgical outcomes and patient quality of life through the use of small-molecule peptides.

Azitra Inc. is a clinical-stage biopharmaceutical company based in Farmington, Connecticut, specializing in microbiome-based therapeutics for skin diseases. Founded in 2014, Azitra leverages extensive scientific research on the skin microbiome to develop innovative treatments for various adverse skin conditions. The company’s proprietary platform includes a microbial library of engineered bacterial strains, notably Staphylococcus epidermidis, which are screened for therapeutic properties. In collaboration with researchers from Yale University and the Jackson Laboratory, Azitra employs advanced technologies such as artificial intelligence and machine learning to analyze and predict the efficacy of its strains. The company focuses on precision dermatology by developing live biotherapeutic products and engineered proteins for topical application, aiming to address unmet medical needs in the dermatological field.

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing innovative therapeutics that inhibit Glycogen Synthase Kinase-3β (GSK-3β), a key enzyme involved in various biological processes linked to cancer and neurodegenerative diseases. Actuate's research primarily targets high-impact cancers, including glioblastoma, ovarian, breast, and pancreatic cancers, as well as conditions such as Alzheimer’s disease, bipolar disorder, and type II diabetes. The company's lead compound, elraglusib, is designed to enter cancer cells and disrupt GSK-3β function, thereby impeding tumor survival and proliferation. Actuate Therapeutics aims to advance its promising drug candidates through clinical development, demonstrating significant anti-tumor activity in challenging cancer types.

Azitra Inc. is a clinical-stage biopharmaceutical company based in Farmington, Connecticut, specializing in microbiome-based therapeutics for skin diseases. Founded in 2014, Azitra leverages extensive scientific research on the skin microbiome to develop innovative treatments for various adverse skin conditions. The company’s proprietary platform includes a microbial library of engineered bacterial strains, notably Staphylococcus epidermidis, which are screened for therapeutic properties. In collaboration with researchers from Yale University and the Jackson Laboratory, Azitra employs advanced technologies such as artificial intelligence and machine learning to analyze and predict the efficacy of its strains. The company focuses on precision dermatology by developing live biotherapeutic products and engineered proteins for topical application, aiming to address unmet medical needs in the dermatological field.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

Lung Therapeutics, Inc. is a pharmaceutical company focused on developing innovative treatments for niche orphan drug indications related to lung injury and disease, particularly fibrosis. Based in Austin, Texas and incorporated in 2012, the company is dedicated to addressing severe complications associated with pneumonia, such as loculated pleural effusion, where fluid accumulation and scar tissue hinder drainage. Its lead product, LTI-01, is an injectable fibrinolytic drug designed to safely clear fibrinous scar tissue, facilitating the drainage of pleural fluid without the need for surgery. In addition to LTI-01, Lung Therapeutics is developing LTI-02 for acute lung injury and LTI-03 for idiopathic pulmonary fibrosis, aiming to enhance treatment pathways for these serious conditions. Through its targeted approach, Lung Therapeutics seeks to improve clinical outcomes for patients with life-threatening lung diseases.

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing innovative therapeutics that inhibit Glycogen Synthase Kinase-3β (GSK-3β), a key enzyme involved in various biological processes linked to cancer and neurodegenerative diseases. Actuate's research primarily targets high-impact cancers, including glioblastoma, ovarian, breast, and pancreatic cancers, as well as conditions such as Alzheimer’s disease, bipolar disorder, and type II diabetes. The company's lead compound, elraglusib, is designed to enter cancer cells and disrupt GSK-3β function, thereby impeding tumor survival and proliferation. Actuate Therapeutics aims to advance its promising drug candidates through clinical development, demonstrating significant anti-tumor activity in challenging cancer types.

IN8bio, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative therapies for cancer treatment utilizing gamma-delta T cells. These immune cells possess the unique ability to distinguish between healthy and diseased tissues, making them promising candidates for cancer therapies. IN8bio employs its DeltEx platform, which incorporates allogeneic, autologous, and genetically modified approaches to create effective cell therapies aimed at targeting and eliminating tumor cells. The company is currently conducting two investigator-initiated Phase 1 clinical trials for its lead product candidates: INB-200, designed for newly diagnosed glioblastoma, and INB-100, aimed at treating patients with high-risk leukemia undergoing hematopoietic stem cell transplantation. In addition to these clinical efforts, IN8bio has a diverse portfolio of preclinical programs targeting various solid tumor types. Founded in 2016 and originally known as Incysus Therapeutics, IN8bio rebranded in August 2020 to reflect its focus on advancing gamma-delta T cell therapies.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

Azitra Inc. is a clinical-stage biopharmaceutical company based in Farmington, Connecticut, specializing in microbiome-based therapeutics for skin diseases. Founded in 2014, Azitra leverages extensive scientific research on the skin microbiome to develop innovative treatments for various adverse skin conditions. The company’s proprietary platform includes a microbial library of engineered bacterial strains, notably Staphylococcus epidermidis, which are screened for therapeutic properties. In collaboration with researchers from Yale University and the Jackson Laboratory, Azitra employs advanced technologies such as artificial intelligence and machine learning to analyze and predict the efficacy of its strains. The company focuses on precision dermatology by developing live biotherapeutic products and engineered proteins for topical application, aiming to address unmet medical needs in the dermatological field.

Lung Therapeutics, Inc. is a pharmaceutical company focused on developing innovative treatments for niche orphan drug indications related to lung injury and disease, particularly fibrosis. Based in Austin, Texas and incorporated in 2012, the company is dedicated to addressing severe complications associated with pneumonia, such as loculated pleural effusion, where fluid accumulation and scar tissue hinder drainage. Its lead product, LTI-01, is an injectable fibrinolytic drug designed to safely clear fibrinous scar tissue, facilitating the drainage of pleural fluid without the need for surgery. In addition to LTI-01, Lung Therapeutics is developing LTI-02 for acute lung injury and LTI-03 for idiopathic pulmonary fibrosis, aiming to enhance treatment pathways for these serious conditions. Through its targeted approach, Lung Therapeutics seeks to improve clinical outcomes for patients with life-threatening lung diseases.

Lantern Pharma Inc. is a clinical-stage biotechnology company based in Dallas, Texas, specializing in the development of precision oncology therapeutics through the integration of artificial intelligence, genomics, and machine learning. The company's lead drug candidate, LP-100, is currently undergoing phase II clinical trials for the treatment of metastatic, castration-resistant prostate cancer. Additionally, Lantern is advancing LP-300 as a combination therapy for female non-smokers with non-small cell lung cancer adenocarcinoma. Another promising candidate in preclinical development is LP-184, an alkylating agent targeting DNA in cancer cells that overexpress specific biomarkers. Lantern Pharma employs its proprietary RADR platform to enhance drug discovery and development, addressing challenges in patient stratification and understanding mechanisms of action, ultimately aiming to accelerate the delivery of personalized cancer therapies. The company was incorporated in 2013 and has positioned itself at the forefront of innovation in oncology.

Azitra Inc. is a clinical-stage biopharmaceutical company based in Farmington, Connecticut, specializing in microbiome-based therapeutics for skin diseases. Founded in 2014, Azitra leverages extensive scientific research on the skin microbiome to develop innovative treatments for various adverse skin conditions. The company’s proprietary platform includes a microbial library of engineered bacterial strains, notably Staphylococcus epidermidis, which are screened for therapeutic properties. In collaboration with researchers from Yale University and the Jackson Laboratory, Azitra employs advanced technologies such as artificial intelligence and machine learning to analyze and predict the efficacy of its strains. The company focuses on precision dermatology by developing live biotherapeutic products and engineered proteins for topical application, aiming to address unmet medical needs in the dermatological field.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.